


Alzheimer's Disease

Impact on Patients, Caregivers and Society and Strategies to Lower the Burden

A growing global public health issue



33–38.5 million people live with AD worldwide¹



Aging populations mean the prevalence is expected to increase to **50 million in 2030 and 95 million in 2050**¹



60% of patients live in low and middle-income countries¹



A major cause of disability

Responsible for **5.6% of DALYs** in people **over 75 years of age in 2019 worldwide**²

Significant human and healthcare costs

Burden on carers

5 hours/day care on average provided by informal carers in 2019¹

70% of **informal care** is provided by **women**³

Estimated global cost



Approximately **0.8 US\$ trillion** in 2019¹

Approximately **1.7 US\$ trillion** in 2030¹

50% is attributed to **informal care**¹

Strategies to improve the lives of patients and their caregivers



Screening and **early diagnosis**³



Social support and interventions to **support caregivers**⁴



Early **pharmacologic interventions** to slow worsening of **cognition, function and behavior**⁵

Interventions to address risk factors such as:



Hearing loss



Hypertension



Depression



Diabetes mellitus

WORLD
MENTAL
HEALTH
DAY



AD, Alzheimer's disease; DALY, disability-adjusted life years.

PROGRESS
IN MIND | Psychiatry & Neurology
Resource Center

References

1. WHO Fact Sheet Dementia. 2 September 2021. Available at: <https://www.who.int/news-room/fact-sheets/detail/dementia>.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–22.
3. Alzheimer's Disease International. World Alzheimer Report 2011. Available at: <https://www.alzint.org/resource/world-alzheimer-report-2011/>.
4. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396:413–46.
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA*. 2004;291(3):317–24.